Lutetium-177-PSMA radioligand therapy in metastatic hormone-sensitive prostate cancer: A systematic review of efficacy, safety, and combination strategies.

Urol OncolJul 18, 2026 (epub)
Clinical ResearchOncology (Medical)

Joseph McGrath, Robert Willis, Sudharshanan Balaji et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluates the efficacy and safety of Lutetium-177-PSMA radioligand therapy (¹⁷⁷Lu-PSMA-RLT) in metastatic hormone-sensitive prostate cancer (mHSPC). Fourteen studies were included, revealing PSA50 rates between 44% and 100%, with median progression-free survival (PFS) ranging from 9.5 to 31.0 months depending on treatment context. Randomized trials showed improved responses compared to controls.

Key findings

  • PSA50 response rates varied from 44% to 100%, highest in treatment-naïve populations.
  • Median PFS ranged from 9.5 months in high-volume cohorts to 31.0 months in combination regimens.
  • Randomized trials demonstrated improved PSA/PFS responses compared to control arms.
  • Toxicity was generally low, with infrequent grade ≥III adverse events.

Why it matters

Understanding the efficacy and safety of ¹⁷⁷Lu-PSMA-RLT in mHSPC is crucial for clinicians considering novel treatment options for patients, particularly those who are treatment-naïve.

What to keep in mind

Current studies face limitations of small sample sizes, heterogeneous protocols, and short follow-up durations.

Source

PubMed · PMID 42471290

Published in Urol Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchPreventive Medicine / Public Health

2025 National Guidelines on the Mediterranean Diet: Executive Summary of a Joint Report by Italian Scientific Societies and the National Institute of Health Task Force on Clinical Practice Guidelines.

This systematic review and practice guideline, developed by a multidisciplinary panel using NUTRIGRADE, assessed Mediterranean diet evidence across nine health domains and one economic domain.

Nutr RevNov 12, 2026Read summary
Clinical ResearchOrthopedic Surgery

Prevention of Venous Thromboembolism after Total Hip or Knee Replacement.

This multicenter randomized comparative-effectiveness noninferiority trial compared 30 days of aspirin, warfarin, or rivaroxaban for VTE prophylaxis after elective total hip or knee arthroplasty.

N Engl J MedNov 12, 2026Read summary
Clinical ResearchAnesthesiology

Effect of discontinuing antihypertensives on perioperative hypotension in older patients before non-cardiac surgery: multicentre, randomised, double blind, controlled trial.

This multicentre, randomised, double blind, placebo controlled trial assessed whether withholding ACE inhibitors or ARBs on the morning of surgery reduces perioperative hypotension in older adults undergoing non-cardiac…

BMJNov 11, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.